https://retatrutidestatus.com/2026-07-30T00:00:00.000Zdaily1.0https://retatrutidestatus.com/about2026-07-30T00:00:00.000Zyearly0.5https://retatrutidestatus.com/approval-timeline2026-07-30T00:00:00.000Zweekly0.9https://retatrutidestatus.com/availability2026-07-30T00:00:00.000Zweekly0.8https://retatrutidestatus.com/clinical-trials2026-07-30T00:00:00.000Zweekly0.8https://retatrutidestatus.com/contact2026-07-30T00:00:00.000Zyearly0.4https://retatrutidestatus.com/corrections2026-07-30T00:00:00.000Zmonthly0.4https://retatrutidestatus.com/fda-approval-status2026-07-30T00:00:00.000Zweekly0.9https://retatrutidestatus.com/medical-disclaimer2026-07-30T00:00:00.000Zyearly0.3https://retatrutidestatus.com/methodology2026-07-30T00:00:00.000Zyearly0.5https://retatrutidestatus.com/news2026-07-30T00:00:00.000Zdaily0.8https://retatrutidestatus.com/news/lilly-states-q1-2027-bla-submission-plan2026-07-30T00:00:00.000Zmonthly0.7https://retatrutidestatus.com/news/transcend-t2d-1-published-in-the-lancet2026-07-30T00:00:00.000Zmonthly0.6https://retatrutidestatus.com/news/triumph-2-and-triumph-3-topline-results2026-07-30T00:00:00.000Zmonthly0.7https://retatrutidestatus.com/phase-3-results2026-07-30T00:00:00.000Zmonthly0.8https://retatrutidestatus.com/price2026-07-30T00:00:00.000Zmonthly0.7https://retatrutidestatus.com/privacy2026-07-30T00:00:00.000Zyearly0.3https://retatrutidestatus.com/sources2026-07-30T00:00:00.000Zweekly0.6https://retatrutidestatus.com/terms2026-07-30T00:00:00.000Zyearly0.3https://retatrutidestatus.com/widget2026-07-30T00:00:00.000Zmonthly0.5